Let's Talk Medtech: Kevin Sayer on Why all eyes are on Dexcom

It's no secret that Dexcom is on the rise. From commercials during the Super Bowl, to blockbuster products on the horizon, the company is reaching a new height of popularity in the continuous glucose monitoring space. Kevin Sayer, Dexcom CEO, talks about the company's new position the space and all the hype surrounding the upcoming G7 CGM sensor. He also gives his thoughts on where CGM technology is headed in this incredible, can't miss conversation.

Episode metadata supplied by the publisher feed · Published Jun 15, 2022

Embed this episode

Attribution link and audio player

Ready to play

Let's Talk Medtech: Kevin Sayer on Why all eyes are on Dexcom

0:00 29:28

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Let’s Talk Medtech?

This episode is 29 minutes long.

When was this Let’s Talk Medtech episode published?

This episode was published on June 15, 2022.

Can I download this Let’s Talk Medtech episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!